{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:26Z","timestamp":1792787306077,"version":"4.5.0"},"reference-count":68,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wellcome Trust Early Career Award","award":["301005\/Z\/23\/Z"],"award-info":[{"award-number":["301005\/Z\/23\/Z"]}],"id":[{"id":"https:\/\/ror.org\/029chgv08","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2026,8,10]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiovascular disease (CVD) and light chain (AL) amyloidosis are important causes of morbidity and mortality in patients with multiple myeloma (MM). Additionally, MM therapies can have cardiovascular effects. However, the extent to which phase III MM trials account for underlying CVD and amyloidosis through eligibility criteria, screening and reporting remains uncertain. These elements of trial design and reporting are essential for accurate interpretation of cardiovascular safety signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine practice-changing MM trials with respect to amyloidosis and CVD eligibility criteria, assessment for cardiac amyloidosis, reporting of baseline cardiovascular characteristics and cardiovascular adverse events (CVAE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic review of phase III randomised controlled trials of MM drug therapies published in English between 2015 and 2025, identified by searching MEDLINE, Embase and Cochrane Library. Eligible trials enrolled adults aged \u226518 years with MM and included \u2265100 patients per treatment group; non-randomised, subgroup and abstract-only reports were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>41 trials enrolling 20\u2009144 participants were included. Amyloidosis was an exclusion criterion in 30 trials typically using non-specific definitions. No trial reported active screening for amyloidosis or assessment of cardiac involvement. Baseline cardiovascular investigations were common but were not used to identify cardiac amyloidosis. At least one cardiovascular exclusion criterion was present in 98% of trials, most commonly heart failure and recent myocardial infarction. Baseline cardiovascular characteristics were reported in only one trial. CVAEs were investigator-reported, inconsistently defined and not centrally adjudicated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Phase III MM trials frequently incorporate amyloidosis and CVD exclusion criteria. However, the prevalence of cardiac amyloidosis and other CVD within these practice-changing MM trials remains poorly defined and CVAE reporting remains suboptimal. These limitations may bias safety and efficacy outcomes and reduce trial generalisability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD420251125097.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2026-004240","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:25:23Z","timestamp":1788261923000},"page":"e004240","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular disease and amyloidosis in phase III multiple myeloma trials: a systematic review of eligibility, screening and event reporting"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8121-682X","authenticated-orcid":false,"given":"Oliver","family":"Henriques Peck","sequence":"first","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK"},{"name":"NHS Greater Glasgow and Clyde, Glasgow, UK"},{"name":"NHS Golden Jubilee University Hospital, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2813-6188","authenticated-orcid":false,"given":"Aimee","family":"McCoubrey","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK"},{"name":"NHS Golden Jubilee University Hospital, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Snowden","sequence":"additional","affiliation":[{"name":"Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"},{"name":"Division of Clinical Medicine. School of Medicine and Population Health, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"University College London (Royal Free Campus), National Amyloidosis Centre, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Travers","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK"},{"name":"NHS Greater Glasgow and Clyde, Glasgow, UK"},{"name":"NHS Golden Jubilee University Hospital, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S","family":"Lees","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK"},{"name":"NHS Greater Glasgow and Clyde, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C","family":"Petrie","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK"},{"name":"NHS Greater Glasgow and Clyde, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninian N","family":"Lang","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Life Sciences, University of Glasgow, Glasgow, UK"},{"name":"NHS Greater Glasgow and Clyde, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2026091603502259000_13.2.e004240.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-358812"},{"key":"2026091603502259000_13.2.e004240.2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/bjh.14058","article-title":"The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials","volume":"174","author":"Robinson","year":"2016","journal-title":"Br J Haematol"},{"key":"2026091603502259000_13.2.e004240.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0554-0"},{"key":"2026091603502259000_13.2.e004240.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2304088"},{"key":"2026091603502259000_13.2.e004240.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"2026091603502259000_13.2.e004240.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724"},{"key":"2026091603502259000_13.2.e004240.7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"2026091603502259000_13.2.e004240.8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cam4.3568","article-title":"Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis","volume":"10","author":"Bishnoi","year":"2021","journal-title":"Cancer Med"},{"key":"2026091603502259000_13.2.e004240.9","article-title":"Bortezomib-Induced Reversible Cardiomyopathy: Recovered With Guideline-Directed Medical Therapy","volume":"13","author":"Sundaravel","year":"2021","journal-title":"Cureus"},{"key":"2026091603502259000_13.2.e004240.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026091603502259000_13.2.e004240.11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.cardfail.2020.07.006","article-title":"Heart Failure with Carfilzomib in Patients with Multiple Myeloma: A Meta-analysis of Randomized Controlled Trials","volume":"27","author":"Rahman","year":"2021","journal-title":"J Card Fail"},{"key":"2026091603502259000_13.2.e004240.12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"2026091603502259000_13.2.e004240.13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaccao.2023.12.010","article-title":"Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials","volume":"6","author":"Rankin","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026091603502259000_13.2.e004240.14","unstructured":"National Institute for Health Research (NIHR) Centre for Reviews and Dissemination University of York . International prospective register of systematic reviews (PROSPERO). 2025. Available: https:\/\/www.crd.york.ac.uk\/prospero\/ [Accessed 12 Aug 2025]."},{"key":"2026091603502259000_13.2.e004240.15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.033502"},{"key":"2026091603502259000_13.2.e004240.16","article-title":"AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor","volume":"13","author":"R\u00edos-Tamayo","year":"2023","journal-title":"Life (Basel)"},{"key":"2026091603502259000_13.2.e004240.17","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","volume":"9","author":"Dimopoulos","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026091603502259000_13.2.e004240.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"2026091603502259000_13.2.e004240.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03739-2"},{"key":"2026091603502259000_13.2.e004240.20","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13020368","article-title":"Amyloid Burden Correlates with Electrocardiographic Findings in Patients with Cardiac Amyloidosis-Insights from Histology and Cardiac Magnetic Resonance Imaging","volume":"13","author":"Duca","year":"2024","journal-title":"J Clin Med"},{"key":"2026091603502259000_13.2.e004240.21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/ehjci\/jez180","article-title":"Diagnostic score of cardiac involvement in AL amyloidosis","volume":"21","author":"Nicol","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026091603502259000_13.2.e004240.22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2028631"},{"key":"2026091603502259000_13.2.e004240.23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","article-title":"Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study","volume":"17","author":"Kistler","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026091603502259000_13.2.e004240.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.059"},{"key":"2026091603502259000_13.2.e004240.25","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00277-022-04959-9","article-title":"Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005-2016","volume":"101","author":"Toppila","year":"2022","journal-title":"Ann Hematol"},{"key":"2026091603502259000_13.2.e004240.26","unstructured":"Food and Drug Administration . Cancer clinical trial eligibility criteria: patients with organ dysfunction or prior or concurrent malignancies guidance for industry. Available: https:\/\/www.fda.gov\/media\/123745\/ [Accessed 05 Nov 2025]."},{"key":"2026091603502259000_13.2.e004240.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.7618"},{"key":"2026091603502259000_13.2.e004240.28","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-210695","article-title":"Cardiovascular Events in Multiple Myeloma: A Retrospective Review of the SEER-Medicare Claims Database","volume":"144","author":"Vardell","year":"2024","journal-title":"Blood"},{"key":"2026091603502259000_13.2.e004240.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1427-1","article-title":"Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis","volume":"17","author":"Hanlon","year":"2019","journal-title":"BMC Med"},{"key":"2026091603502259000_13.2.e004240.30","unstructured":"National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE) Version 6.0. Available: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events [Accessed 05 Nov 2025]."},{"key":"2026091603502259000_13.2.e004240.31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab674"},{"key":"2026091603502259000_13.2.e004240.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"2026091603502259000_13.2.e004240.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"2026091603502259000_13.2.e004240.34","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00128-5"},{"key":"2026091603502259000_13.2.e004240.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"2026091603502259000_13.2.e004240.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"2026091603502259000_13.2.e004240.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"2026091603502259000_13.2.e004240.38","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.clml.2023.02.009","article-title":"Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study","volume":"23","author":"Fu","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026091603502259000_13.2.e004240.39","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026091603502259000_13.2.e004240.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"2026091603502259000_13.2.e004240.41","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA)","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"2026091603502259000_13.2.e004240.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4"},{"key":"2026091603502259000_13.2.e004240.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"2026091603502259000_13.2.e004240.44","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"2026091603502259000_13.2.e004240.45","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1182\/bloodadvances.2024013101","article-title":"A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"8","author":"Dimopoulos","year":"2024","journal-title":"Blood Adv"},{"key":"2026091603502259000_13.2.e004240.46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"2026091603502259000_13.2.e004240.47","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02060"},{"key":"2026091603502259000_13.2.e004240.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"2026091603502259000_13.2.e004240.49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-874396"},{"key":"2026091603502259000_13.2.e004240.50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2016.176","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)","volume":"31","author":"H\u00e1jek","year":"2017","journal-title":"Leukemia"},{"key":"2026091603502259000_13.2.e004240.51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30452-6"},{"key":"2026091603502259000_13.2.e004240.52","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"2026091603502259000_13.2.e004240.53","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/bjh.16287","article-title":"Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse","volume":"188","author":"Montefusco","year":"2020","journal-title":"Br J Haematol"},{"key":"2026091603502259000_13.2.e004240.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"2026091603502259000_13.2.e004240.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"2026091603502259000_13.2.e004240.56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-613927"},{"key":"2026091603502259000_13.2.e004240.57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-662627"},{"key":"2026091603502259000_13.2.e004240.58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679415"},{"key":"2026091603502259000_13.2.e004240.59","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"key":"2026091603502259000_13.2.e004240.60","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4"},{"key":"2026091603502259000_13.2.e004240.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"2026091603502259000_13.2.e004240.62","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026091603502259000_13.2.e004240.63","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"2026091603502259000_13.2.e004240.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"2026091603502259000_13.2.e004240.65","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"2026091603502259000_13.2.e004240.66","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3026(21)00381-1","article-title":"Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study","volume":"9","author":"Schjesvold","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026091603502259000_13.2.e004240.67","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.clml.2024.05.014","article-title":"Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study","volume":"24","author":"Oriol","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026091603502259000_13.2.e004240.68","unstructured":"Puig N , Hern\u00e1ndez MT , Rosi\u00f1ol L , et al . Randomized trial of lenalidomide and dexamethasone versus clarithromycin, lenalidomide and dexamethasone as first line treatment in patients with multiple myeloma not candidates for autologous stem cell transplantation: results of the GEM-Claridex clinical trial. Blood 2019;134."}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2026-004240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:50:45Z","timestamp":1789555845000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2026-004240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":68,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/openhrt-2026-004240"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2026-004240","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}